Quantitative Neuromuscular Monitoring and Gastric Bypass Surgery
Recruiting
- Conditions
- Sugammadex
- Registration Number
- NCT05886218
- Lead Sponsor
- University of California, Davis
- Brief Summary
This is a single site, prospective, non-blinded, non-randomized, before/after study. This study is designed to evaluate the impact of monitoring and reversal guidelines for neuromuscular blocking drugs on the post-operative outcomes for patients undergoing laparoscopic gastric bypass surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 215
Inclusion Criteria
- age greater than 18 years
- scheduled for an elective laparoscopic gastric bypass procedure
Exclusion Criteria
- age less than 18 years
- pregnancy
- prisoners
- significant co-existing lung disease including asthma or chronic obstructive pulmonary disease (COPD) requiring regular medication
- patients who require supplemental oxygen pre-operatively to maintain a hemoglobin saturation (SpO2>98%)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Oxygen desaturation 24 hours Incidence and magnitude of significant oxygen desaturation
- Secondary Outcome Measures
Name Time Method Total intraoperative rocuronium use 24 hours Total dose/kg/hr (mg/kg/hr)
Post-operative supplemental oxygen requirement 24 hours Oxygen requirement (FiO2%/hr)
Post-operative unit length of stay 7 days Length of stay (Hours)
Total sugammadex dose 24 hours Total dose (mg/kg)
The rate of compliance with muscle relaxant monitoring and reversal protocols 24 hours Rate of compliance (%)
Success rate for wearable device 24 hours Rate of compliance (%)
Hospital Length of stay 7 days Length of stay (Hours)
Trial Locations
- Locations (1)
UC Davis Medical Center
🇺🇸Sacramento, California, United States